Menu

Drug-Industry Funded Study Finds Utilization Drives 340B Program Growth, Not Rising Drug Prices

Bella Czajkowski, National Correspondent 340B Report Views
A recent drug-industry funded study in Health Affairs Scholar found that increased utilization, rather than rising drug prices, drives 340B program growth.
A recent drug-industry-funded study attributes the 340B program’s recent growth to increased utilization—not rising drug prices. The May 21 study, [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Post Navigation

In Emergency Motion, Novartis and BMS Urge Appellate Court to Fast-Track Their Appeals of 340B Rebate Ruling

Sandoz to Stop Notifying CEs of 340B Contract Pharmacy Changes, Joins Liquidia in Adding Restrictions to New Drugs; Novartis Updates Restrictions

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live

Sliding Sidebar

Link to spotlight on Sean Hall of Visante

340B Report Categories

More Categories

Recent Articles

Article Archives